This segment focuses on the research, development, and manufacturing of rapid, point-of-care diagnostic tests. Lumos Diagnostics utilizes its expertise in microfluidics, lateral flow assays, and reader technology to create innovative diagnostic solutions. Key activities include assay development, reagent optimization, and manufacturing process improvement. The company's product portfolio includes tests for infectious diseases, such as FebriDx (differentiating bacterial and viral respiratory infections), ViraDx (combined COVID/Influenza test), and CoviDx (COVID-19 antigen test). These tests aim to provide rapid and accurate results at the point of care, enabling timely clinical decision-making and improved patient outcomes. Lumos Diagnostics leverages its proprietary technologies and manufacturing capabilities to maintain a competitive edge in the point-of-care diagnostics market. Future opportunities include expanding the product portfolio to address additional disease areas and developing next-generation diagnostic platforms.

Lumos Diagnostics provides specialized contract research and development services focused on the innovation, development, commercialization, and manufacturing of point-of-care diagnostic solutions for clinical and consumer applications. This segment leverages the company's expertise in assay development, microfluidics, and manufacturing to support external partners in developing and commercializing their own diagnostic products. Key activities include feasibility studies, assay design, prototype development, manufacturing scale-up, and regulatory support. Lumos Diagnostics works with a variety of clients, including pharmaceutical companies, diagnostic developers, and research institutions. The company's contract R&D services enable partners to accelerate product development, reduce costs, and access specialized expertise. Future opportunities include expanding the service offerings to include additional diagnostic modalities and therapeutic areas, as well as establishing strategic partnerships with key industry players.